ArticleJournal of Cancer2019
Transarterial Chemoembolization (TACE) Combined with Sorafenib
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05171166 (Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven), which is not on this map. Cited by 28 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.
Who cites it
28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.Journal of the Egyptian National Cancer Institute · 2024Pooled it
- External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.World journal of surgical oncology · 2023Pooled it
- Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis.Frontiers in oncology · 2023Pooled it
- The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.World journal of surgical oncology · 2020Pooled it
- Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis.Journal of gastrointestinal oncology · 2026Article
- Arterial and biliary complications after transarterial chemoembolization for hepatocellular carcinoma.World journal of clinical oncology · 2026Review
- Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.Journal of cancer research and clinical oncology · 2025Review
- Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.BMC cancer · 2024Article
- Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Systemic Treatment in Intermediate Stage (Barcelona Clinic Liver Cancer-B) Hepatocellular Carcinoma.Cancers · 2023Review
- A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy.Frontiers in cell and developmental biology · 2023Review
- Review
- The advanced development of molecular targeted therapy for hepatocellular carcinoma.Cancer biology & medicine · 2022Review
- Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma.Annals of translational medicine · 2021Review
- Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis.Life (Basel, Switzerland) · 2021Article
- Combination therapy with percutaneous osteoplasty and transcatheter arterial chemoembolization for the treatment of pelvic bone metastases: preliminary report.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.Annals of translational medicine · 2021Article
- Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.Cancer management and research · 2021Article
- Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT.Journal of oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.